Related Experiment Video

Updated: May 24, 2025

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.4K

BCMA-targeted therapies for multiple myeloma: latest updates from 2024 ASH annual meeting

Huijian Zheng1, Huajian Xian2, Wenjie Zhang1

  • 1Fujian Provincial Key Laboratory on Hematology, Fujian Institute of Hematology, Fujian Medical University Union Hospital, 29 Xinquan Rd, Fuzhou, 350001, China.

Journal of Hematology & Oncology
|March 2, 2025
PubMed

Insights

B-cell maturation antigen (BCMA) is a key target for multiple myeloma (MM). Latest research highlights antibody-drug conjugates (ADCs), bispecific antibodies (BsAbs), and CAR-T cell therapies for MM treatment.

Area of Science:

  • Hematology
  • Oncology
  • Immunotherapy

Background:

  • B-cell maturation antigen (BCMA) is a primary therapeutic target in multiple myeloma (MM).
  • BCMA-targeted therapies represent a significant advancement in MM treatment strategies.
  • The 2024 American Society of Hematology (ASH) Annual Meeting showcased novel developments in BCMA-directed treatments.

Discussion:

  • Antibody-drug conjugates (ADCs) deliver cytotoxic agents directly to BCMA-expressing cells.
  • Bispecific antibodies (BsAbs) engage both T-cells and BCMA-expressing myeloma cells.
  • Chimeric antigen receptor T (CAR-T) cell therapy redirects a patient's own T-cells to target BCMA.

Key Insights:

  • All three modalities—ADCs, BsAbs, and CAR-T cells—demonstrated promising efficacy in preclinical and clinical studies.
  • Emerging data suggest potential for deep and durable responses across different patient populations.
  • Comparisons of efficacy, safety, and logistical considerations are crucial for clinical decision-making.

Outlook:

  • Continued research will refine patient selection and optimize treatment protocols for BCMA-targeted therapies.
  • Combination strategies involving BCMA-targeted agents may further enhance therapeutic outcomes.
  • The development pipeline for BCMA-targeted therapies remains robust, offering hope for improved MM management.
Keywords:
ASH 2024BCMA-targeted therapiesMultiple myeloma

More Related Videos

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

6.7K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.3K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
461
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.5K